June 21, 2017 10:01 AM EDT

Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment

Emma Yasinski

→ Cambridge, MA-based Sarepta $SRPT is doubling down on new work focused on developing a gene therapy for Duchenne muscular dystrophy. The biotech inked …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment

Emma Yasinski

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Novo Nordisk CEO to step down, timeline for successor unknown

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

Novo Nordisk’s global obesity leader is moving on; Flagship biotech gets CEO from Scholar Rock

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

It's been three months without a biotech IPO

RFK Jr. adopts new chikungunya vaccine guidance; other recommendations remain under review

Sarep­ta to col­lab­o­rate with Genethon on DMD gene ther­a­py; Chi­nese in­vestors pull back on Pluris­tem in­vest­ment

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment